Cantor Fitzgerald’s Travere Therapeutics TVTX Stock Holding History

Cantor Fitzgerald’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35,748	Closed	-$500K	–	340
2024 Q3	$500K	Buy	+35,748	New	+$372K	0.01%	94

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cantor Fitzgerald's TVTX Position: Q4 2024 in Review

Cantor Fitzgerald sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 35,748 shares — an estimated $500K sold.

Cantor Fitzgerald first reported a position in TVTX in Q3 2024 and held it in 1 quarter. The position peaked at $500K in Q3 2024. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

Cantor Fitzgerald reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
Cantor Fitzgerald sold 35,748 Travere Therapeutics shares in Q4 2024, an estimated $500K.
Cantor Fitzgerald first reported a position in Travere Therapeutics in Q3 2024 and held it in 1 quarter.
Cantor Fitzgerald's Travere Therapeutics position peaked at $500K in Q3 2024.
197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Cantor Fitzgerald's 13F filing for Q4 2024, filed 14 Feb 2025.